HOME >> MEDICINE >> NEWS
Duke/Novalon researchers identify potential mechanism behind tamoxifen resistance in breast cancers

DURHAM, N.C. -- Scientists have identified a likely reason why the breast cancer drug tamoxifen stops working in women who use it for more than five years. They say their discovery could lead to new drugs that either work better than tamoxifen or prevent a woman's resistance to the drug.

The researchers, from Duke University Medical Center and Novalon Pharmaceutical Corp., reported in the July 30 issue of Science that tamoxifen initiates a cascade of changes inside the breast cell that are far different from the effects of estrogen or other compounds that rouse the estrogen receptor into action.

Tamoxifen's desired action is to block the effects of estrogen, a hormone involved in the growth of half of all breast cancers. It works by binding to the estrogen receptor and blocking estrogen from docking to it. Hence, tamoxifen has been called an "anti-estrogen." Later, however, tamoxifen begins to lose its effectiveness, and researchers have long wondered why.

Now, they have learned that instead of acting like either an estrogen or an anti-estrogen, tamoxifen has its own distinct properties that drive the cell's estrogen receptor into a different shape than estrogen or other estrogen "mimics" would. The shape the receptor takes determines how the cell will behave and what activity it will generate.

In the case of tamoxifen, the researchers found that it causes the estrogen receptor in breast cells to form an additional and unique "pocket" or surface -- a place where other proteins inside the cell can bind to or dock themselves. While these proteins have yet to be identified, the researchers say their action of binding to this new pocket on the receptor is what changes the cell's response to tamoxifen. For reasons unknown, the cells then begin to see tamoxifen as an estrogen instead of an anti-estrogen, and hence the cancer once again proliferates.

"The implications of our discovering this new pocket fo
'"/>

Contact: Rebecca A. Levine
Levin005@mc.duke.edu
919-684-4148
Duke University Medical Center
30-Jul-1999


Page: 1 2 3 4

Related medicine news :

1. Indiana University researchers closer to helping hearing-impaired using stem cells
2. Protein that helps skin cancer spread identified by Stanford researchers
3. US life expectancy about to decline, researchers say
4. Gene for age-related macular degeneration discovered by Yale researchers
5. Dartmouth researchers find where musical memories are stored in the brain
6. Columbia researchers receive $3 million to combat genetic killer of infants & toddlers
7. US cancer researchers launch first American-Israeli cancer conference
8. USC dental researchers develop first test for predicting cavities in children
9. Young blood revives aging muscles, Stanford researchers find
10. Uric acid may help reduce effects of spinal cord injury, Jefferson researchers find
11. Age should not be a factor in determining heart transplantation eligibility, researchers say

Post Your Comments:
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
(Date:10/31/2014)... By Steven Reinberg HealthDay ... skin condition eczema may increase slightly the risk of broken bones ... of 34,500 adults, researchers found that among 7 percent of people ... had a bone or joint injury and 0.6 percent had an ... people without eczema, those with the skin condition had more than ...
(Date:10/30/2014)... for injuries and damage to the joints, including articular ... a hard material that caps the ends of bones ... engineers, exploring ways to toughen up engineered cartilage and ... developments this week in the journal Proceedings of ... with engineered tissue is that the mechanical properties are ...
(Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
(Date:10/30/2014)... Don Allred Insurance, a leading provider ... for North Carolina residents, is excited to announce the ... Hill Mall. The new branch has been up and ... through all facets of the insurance selection process from ... Scott Allred couldn’t be happier with the timing of ...
Breaking Medicine News(10 mins):Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2
(Date:10/31/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.279 ... or $(0.04) per share. These results compare to net ... $50 thousand, or $(0.01) per share, in the year-ago ...
(Date:10/31/2014)... October 30, 2014 ... the addition of the  "Process Validation in the ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key ... Risk Based Approach to Process Validation for Pharmaceutical ... FDA Process Validation Guidance ...
(Date:10/31/2014)... 2014  AbbVie (NYSE: ABBV ) ... ended Sept. 30, 2014. "Our ... business with double-digit growth from HUMIRA and several ... 14 percent in the quarter excluding lipids," said ... AbbVie.  "We exceeded our outlook for the quarter ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
Cached News: